Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) - Inoue, A; Kobayashi, K; Maemondo, M (Ann Oncol, 2013)
, et al; North-East Japan Study Group.